Deborah L. V. Keller Tanner serves as Independent Director of the Company. Ms. Keller serves as a Principal at Black Frame Advisors, LLC, having recently retired as CEO of Covance Drug Development—a business segment of Laboratory Corporation of America Holdings. Prior to serving as CEO, Ms. Keller spent more than 28 years at Covance in several leadership roles, including Corporate Executive Vice President and Group President of Research and Development Laboratories, Corporate Senior Vice President and President of Discovery and Translational Services, and Vice President of Analytical Services in Europe. She is a trustee of the Wisconsin Alumni Research Foundation, Operating Partner of HealthCloud Capital Fund and serves on the Dean's Advisory Board for the University of Wisconsin School of Business, where she is also an adjunct professor. Ms. Keller was named one of FierceBiotech's 10 Top Women in Biotech in 2012.
As the Independent Director of West Pharmaceutical Services, the total compensation of Deborah Tanner at West Pharmaceutical Services is $283,862. There are 18 executives at West Pharmaceutical Services getting paid more, with Eric Green having the highest compensation of $6,533,690.
Deborah Tanner is 57, she's been the Independent Director of West Pharmaceutical Services since 2017. There are 10 older and 16 younger executives at West Pharmaceutical Services. The oldest executive at West Pharmaceutical Services, Inc. is Patrick Zenner, 73, who is the Independent Chairman of the Board.
Deborah's mailing address filed with the SEC is 530 HERMAN O. WEST DRIVE, , EXTON, PA, 19341.
Over the last 19 years, insiders at West Pharmaceutical Services have traded over $32,829,857 worth of West Pharmaceutical Services stock and bought 19,924 units worth $1,139,950 . The most active insiders traders include Robert F Friel, Paolo Pucci, and Douglas A Michels. On average, West Pharmaceutical Services executives and independent directors trade stock every 40 days with the average trade being worth of $4,786,805. The most recent stock trade was executed by Charles Witherspoon on 19 August 2024, trading 1,029 units of WST stock currently worth $308,700.
west works side-by-side with healthcare partners from concept to the patient, designing and manufacturing packaging and delivery systems that promote efficiency, reliability and safety. west leads the way with cutting-edge technologies and quality systems, a thorough understanding of global regulatory compliance, and an unmatched knowledge of relevant pharmaceutical product testing, development and packaging. west supports customers from sales, manufacturing, and research and development locations in north and south america, europe, asia and australia.
West Pharmaceutical Services executives and other stock owners filed with the SEC include: